Cancer Chemotherapy and Pharmacology

, Volume 61, Issue 3, pp 349–354 | Cite as

Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer

Review
First Online:
Received:
Accepted:

Abstract

Background

Oxaliplatin, a platinum derivative used in the treatment of gastrointestinal cancers, has been associated with sensory neuropathies and, more infrequently, a neuromyotonia-like hyperexcitability syndrome. We present a case of hyperexcitability syndrome that developed during the treatment of pancreatic cancer with oxaliplatin and gemcitabine (GEMOX) that was successfully treated with pregabalin.

Case presentation

A 54-year-old woman was undergoing chemotherapy with gemcitabine and oxaliplatin (GEMOX) for stage II-B pancreatic adenocarcinoma. On the third day of her fourth cycle, she presented with twitching of eyelids and tremors of hands. This twitching started bilaterally on the eyelids, followed by teeth jittering, hand shaking, and slurring of speech. A thorough neurological exam revealed no abnormalities except increased tone of both hands—she had difficulty opening her hand after closing it for a hand-grip. She was given a dose of 1 g of IV magnesium sulfate and 1 g of IV calcium gluconate, and 50 mg of IV diphenhydramine. In addition to reassurance, pregabalin was prescribed for these myotonic symptoms at a dosage of 50 mg by mouth three times daily. Improvement occurred in these symptoms within 12 h and she was almost asymptomatic within 72 h.

Conclusion

Oxaliplatin causes a unique spectrum of acute neurological toxicities that have not been observed in patients receiving either cisplatin or carboplatin. Clinically, sensory alterations are most prominent, particularly cold-induced and perioral paresthesias. Other symptoms, such as cramps, jaw stiffness, voice changes, ptosis, and visual field changes suggest that motor nerves or muscles may also be involved (hyperexcitability). Hyperexcitability syndrome, distinct from cold-induced paresthesias and sensory neuropathy, is a rare complication of oxaliplatin chemotherapy; and up to date no pharmacotherapy has been successful in treating these symptoms. This is the first report of the successful amelioration of this syndrome with the antiepileptic pregabalin.

Keywords

Oxaliplatin Hyperexcitability syndrome Myotonia Colon cancer Peripheral neuropathy Sodium channels 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Package insert. Eloxatin (oxaliplatin). Sanofi-Synthelabo, New York, July 2004Google Scholar
  2. 2.
    Bleiberg H, de Gramont A (1998) Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol 25:32–39PubMedGoogle Scholar
  3. 3.
    Becouarn Y, Rougier P (1998) Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. Semin Oncol 25:23–31PubMedGoogle Scholar
  4. 4.
    De Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947PubMedGoogle Scholar
  5. 5.
    Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29(5 suppl 15):21–33PubMedCrossRefGoogle Scholar
  6. 6.
    Leonard GD, Wright MA, Quinn MG, Harold N, Schuler B, Thomas RR, Grem JL (2005) Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 16(5):116CrossRefGoogle Scholar
  7. 7.
    Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK (2004) Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29(3):387–392PubMedCrossRefGoogle Scholar
  8. 8.
    Auger RG (1994) Diseases associated with excess motor unit activity. Muscle Nerve 17:1250–1263PubMedCrossRefGoogle Scholar
  9. 9.
    Zielasek J, Martini R, Suter U et al (2000) Neuromyotonia in mice with hereditary myelinopathies. Muscle Nerve 23:696–701PubMedCrossRefGoogle Scholar
  10. 10.
    Reeback J, Benton S, Swash M et al (1979) Penicillamine-induced neuromyotonia. BMJ 1:1464–1465PubMedGoogle Scholar
  11. 11.
    Caldron PH, Wilbourn AJ (1988) Gold neurotoxicity and myokymia. J Rheumatol 15:528–529PubMedGoogle Scholar
  12. 12.
    Bostock H, Burke D, Hales JP (1994) Differences in behaviour of sensory and motor axons following release of ischaemia. Brain 117:225–234PubMedCrossRefGoogle Scholar
  13. 13.
    Nagado T, Arimura K, Sonoda Y et al (1999) Potassium current suppression in patients with peripheral nerve hyperexcitability. Brain 122:2057–2066PubMedCrossRefGoogle Scholar
  14. 14.
    Maddison P, Newsom-Davis J, Mills KR (1999) Strength-duration properties of peripheral nerve in acquired neuromyotonia. Muscle Nerve 22:823–830PubMedCrossRefGoogle Scholar
  15. 15.
    Hart IK, Waters C, Vincent A et al (1997) Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 41:238–246PubMedCrossRefGoogle Scholar
  16. 16.
    Vincent A (2000) Understanding neuromyotonia. Muscle Nerve 23:655–657PubMedCrossRefGoogle Scholar
  17. 17.
    Hart IK (2000) Acquired neuromyotonia. A new autoantibody-mediated neuronal potassium channelopathy. Am J Med Sci 319:209–216PubMedCrossRefGoogle Scholar
  18. 18.
    Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20(7):1767–1774PubMedCrossRefGoogle Scholar
  19. 19.
    Mitchell PL, Goldstein D, Michael M, Beale P, Friedlander M, Zalcberg J, White S, Thomson JA, Clarke S (2006) Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 6(2):146–151PubMedCrossRefGoogle Scholar
  20. 20.
    Mariani G, Garrone O, Granetto C et al (2000) Oxaliplatin-induced neuropathy: could gabapentin be the answer. Proc Am Soc Clin Oncol 19:609, (abstract 2397)Google Scholar
  21. 21.
    Fehrenbacher JC, Taylor CP, Vasko MR (2003) Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 105(1–2):133–141PubMedCrossRefGoogle Scholar
  22. 22.
    Frampton JE, Foster RH (2005) Pregabalin in the treatment of postherpetic neuralgia. Drugs 65(1):111–120PubMedCrossRefGoogle Scholar
  23. 23.
    Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M (2005) Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of fble- and fixed-dose regimens. Pain 115(3):254–263PubMedGoogle Scholar
  24. 24.
    Wesche D, Bockbrader H (2005) A pharmacokinetic comparison of pregabalin and gabapentin. http://www.ampainsoc.org/abstract/2005/data/684/index.html. Accessed 22 June
  25. 25.
    Lahrmann H, Albrecht G, Drlicek M, Oberndorfer S, Urbanits S, Wanschitz J et al (2001) Acquired neuromyotonia and peripheral neuropathy in a patient with Hodgkin’s disease. Muscle Nerve 24:834–838PubMedCrossRefGoogle Scholar
  26. 26.
    Auger RG (1994) AAEM minimonograph #44: diseases associated with excess motor unit activity. Muscle Nerve 17:1250–1263PubMedCrossRefGoogle Scholar
  27. 27.
    Shillito P, Molenaar PC, Vincent A, Leys K, Zheng W, van den Berg RJ et al (1995) Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol 38:714–722PubMedCrossRefGoogle Scholar
  28. 28.
    Saif MW, Reardon J (2005) Management of oxaliplatin-induced peripheral neuropathy. Therap Clin Risk Manage 1(4):249–248Google Scholar
  29. 29.
    FDA approval letter of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy. Department of Health & Human Services. http://www.fda.gov/cder/foi/appletter/2004/21446ltr.pdf
  30. 30.
    Shneker B, McAuley JW (2005) Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother 39(12):2029–2037PubMedCrossRefGoogle Scholar
  31. 31.
    Saif MW (2004) Oral calcium ameliorating oxaliplatin-induced peripheral neuropathy. J Appl Res 4(4):576–582Google Scholar
  32. 32.
    CONCEPT Comparison of oxaliplatin vs. conventional methods with calcium/magnesium in first-line metastatic colorectal cancer. http://www.clinicaltrials.gov/ct/show/NCT00129870. Accessed 11 Aug 2007

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Section of Medical OncologyYale University School of MedicineNew HavenUSA
  2. 2.Griffin Hospital, DerbyNew HavenUSA

Personalised recommendations